Deep knowledge on
small-molecule drugs and
the 90,000 global patents
covering them

Request a free trial

No credit card. No commitment.

Plans and Pricing

DrugPatentWatch Ultimate Plan Preview

Details for Generic Name: doxepin hydrochloride

« Back to Dashboard
Doxepin hydrochloride is the generic ingredient in four branded drugs marketed by Dava Pharms Inc, Mutual Pharm, Mylan Pharms Inc, New River, Par Pharm, Purepac Pharm, Quantum Pharmics, Sandoz, Watson Labs, Pfizer, Pharm Assoc, Silarx, Teva Pharms, Wockhardt, Delcor Asset Corp, Actavis Elizabeth, and Pernix Theraps Llc, and is included in fifty-eight NDAs. There are nine patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

This ingredient has fifty-three patent family members in seventeen countries.

There are seven drug master file entries for doxepin hydrochloride. Six suppliers are listed for this compound. There are three tentative approvals for this compound.

Summary for Generic Name: doxepin hydrochloride

Tradenames:4
Patents:9
Applicants:17
NDAs:58
Drug Master File Entries: see list7
Suppliers / Packaging: see list17
Therapeutic Class:Antidepressants
Anxiolytics
Dermatological Agents
Formulation / Manufacturing:see details

Pharmacology for Ingredient: doxepin hydrochloride

Tentative approvals for DOXEPIN HYDROCHLORIDE

Applicant Application No. Form Dosage
<disabled><disabled>TABLET; ORAL3MG
<disabled><disabled>TABLET; ORAL6MG
<disabled><disabled>TABLET; ORAL3MG

Clinical Trials for: doxepin hydrochloride

Doxepin Hydrochloride in Treating Esophageal Pain in Patients With Thoracic Cancer Receiving Radiation Therapy to the Thorax With or Without Chemotherapy
Status: Recruiting Condition: Lymphoma; Malignant Mesothelioma; Malignant Pericardial Effusion; Malignant Pleural Effusion; Non-small Cell Lung Cancer; Small Cell Lung Cancer; Soft Tissue Sarcoma; Thymoma and Thymic Carcinoma

Safety and Efficacy of Ramelteon and Doxepin in Subjects With Chronic Insomnia
Status: Completed Condition: Sleep Initiation and Maintenance Disorders

Doxepin Hydrochloride in Treating Oral Mucositis Pain in Patients With Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy
Status: Active, not recruiting Condition: Head and Neck Cancer; Mucositis; Oral Complications of Radiation Therapy; Pain

Topical Doxepin for Radiation-induced Dermatitis
Status: Recruiting Condition: Breast Cancer

Doxepin and a Topical Rinse in the Treatment of Acute Oral Mucositis Pain in Patients Receiving Radiotherapy With or Without Chemotherapy
Status: Recruiting Condition: Acute Oral Mucositis Pain

Assess the Effect of a Single Dose of Zolpidem, Silenor & Placebo on Arousability, Ataxia/Balance & Cognitive Performance in Healthy Volunteers
Status: Not yet recruiting Condition: Healthy

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Purepac Pharm
DOXEPIN HYDROCHLORIDE
doxepin hydrochloride
CAPSULE;ORAL072386-001Sep 8, 1988DISCNNo<disabled><disabled>
Par Pharm
DOXEPIN HYDROCHLORIDE
doxepin hydrochloride
CAPSULE;ORAL071422-001Nov 9, 1987DISCNNo<disabled><disabled>
Pernix Theraps Llc
SILENOR
doxepin hydrochloride
TABLET;ORAL022036-002Mar 17, 2010RXYes6,211,229<disabled><disabled>
Watson Labs
DOXEPIN HYDROCHLORIDE
doxepin hydrochloride
CAPSULE;ORAL071763-001Feb 9, 1988DISCNNo<disabled><disabled>
Pernix Theraps Llc
SILENOR
doxepin hydrochloride
TABLET;ORAL022036-002Mar 17, 2010RXYes6,103,219<disabled>Y<disabled>
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: doxepin hydrochloride

Country Document Number Publication Date
Hungary9602361Dec 28, 2001
World Intellectual Property Organization (WIPO)2007142811Mar 13, 2008
Taiwan505529Oct 11, 2002
World Intellectual Property Organization (WIPO)2007142810Mar 13, 2008
Germany69638054Nov 26, 2009
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013   2014  

For more information try a free trial or see the plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2015 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn
`abc